未找到相关数据
A real-world study on implementation of new therapeutic options, especially bevacizumab, in a cohort of HER2-negative metastatic breast cancer patients treated with first-line chemotherapy
被引：0
作者：
Van Kampen, Roel J. W.
Lobbezoo, Dorien J. A.
De Boer, Maaike
Voogd, Adri C.
Dercksen, Wouter
van den Berkmortel, Franchette W. P. J.
Smilde, Tineke Jacoba
Van de Wouw, Agnes W.
Peters, Frank P. J.
Van Riel, Johanna M. G.
Peters, Natascha A. J. B.
Borm, George F.
Joore, Manuela A.
Tjan-Heijnen, Vivianne C.
机构：
[1] Maastricht Univ, Med Ctr, Div Med Oncol, Dept Internal Med,GROW, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Epidemiol, GROW, Maastricht, Netherlands
[3] Maxima Med Ctr, Eindhoven, Netherlands
[4] Atrium Med Ctr, Heerlen, Netherlands
[5] Jeroen Bosch Hosp, Den Bosch, Netherlands
[6] Viecuri Med Ctr, Venlo, Netherlands
[7] Orbis Med Ctr, Sittard, Netherlands
[8] St Elizabeth Hosp, Tilburg, Netherlands
[9] St Jans Hosp, Weert, Netherlands
[10] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6525 ED Nijmegen, Netherlands
[11] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17549
引用
收藏
页数：1
相关论文